Table 3.
MMP levels by group
| Plasma | HIV | Control (Group 0) | t-test | CSF | HIV |
|---|---|---|---|---|---|
|
| |||||
| n=52 | n=21 | p-value | n=9 | ||
| MMP-1 | 1,179 ± 925 | 1,013 ± 627 | 0.457 | MMP-1 | Undetectable |
| MMP-2 | 41,740 ± 13,123 | 58,800 ± 13,970 | <0.001** | MMP-2 | 6,700 ± 2,297 |
| MMP-7 | 4,989 ± 2,348 | 4,415 ± 1,731 | 0.318 | MMP-7 | Undetectable |
| MMP-9a | 41,606 ± 38,926 | 33,385 ± 16,230 | 0.958 | MMP-9 | 345 ± 375 |
| MMP-10 | 544 ± 342 | 471 ± 123 | 0.347 | MMP-10 | Undetectable |
| Subgroups | Group 1 | Group 2 | ANOVA | Planned t-tests (p-value) | ||
|---|---|---|---|---|---|---|
| EIA Group | Nonreactive (n=13) | Reactive (n=39) | p-value | 0/1 | 0/2 | 1/2 |
| MMP-1 | 1,335 ± 1,060 | 1,138 ± 898 | 0.614 | 0.296 | 0.575 | 0.553 |
| MMP-2 | 49,675 ± 12,659 | 39,653 ± 12,582 | <0.001** | 0.091† | <0.001** | 0.030* |
| MMP-7 | 5,952 ± 2,757 | 4,737 ± 2,200 | 0.178 | 0.067† | 0.566 | 0.147 |
| MMP-9a | 47,565 ± 65,512 | 40,038 ± 29,474 | 0.769 | 0.583 | 0.788 | 0.493 |
| MMP-10 | 556 ± 299 | 540 ± 356 | 0.638 | 0.406 | 0.391 | 0.901 |
| ARV Status | Naïve (n=27) | Initiated (n=25) | p-value | 0/1 | 0/2 | 1/2 |
| MMP-1 | 1,079 ± 752 | 1,279 ± 1,079 | 0.547 | 0.753 | 0.328 | 0.461 |
| MMP-2 | 45,164 ± 13,226 | 38,318 ± 12,351 | <0.001** | 0.002** | <0.001** | 0.070† |
| MMP-7 | 4,747 ± 2,384 | 5,232 ± 2,337 | 0.455 | 0.600 | 0.198 | 0.480 |
| MMP-9a | 35,073 ± 43,245 | 48,139 ± 33,723 | 0.050* | 0.246 | 0.211 | 0.016* |
| MMP-10 | 559 ± 311 | 529 ± 377 | 0.606 | 0.212 | 0.484 | 0.762 |
MMP measurements are in units of pg/mL.
CSF: Cerebrospinal fluid; EIA: Early Infection Assay; ARV: Antiretroviral.
a
Kruskal-Wallis and Mann-Whitney tests used for MMP-9.
**
Significant at the 0.01 level.
*
Significant at the 0.05 level.
†
Nearly significant (p < 0.10).